Medical cannabis: Exploring therapeutic perspectives and regulatory context
1 Laboratory of Pharmacognosy, Faculty of Pharmacy, University of Algiers-1, Algeria.
2 Hussein Dey University Hospital Center, Algiers, Algeria.
Review Article
GSC Biological and Pharmaceutical Sciences, 2023, 24(01), 240–251.
Article DOI: 10.30574/gscbps.2023.24.1.0287
Publication history:
Received on 10 June 2023; revised on 16 July 2023; accepted on 19 July 2023
Abstract:
The utilization of medical cannabis, specifically the therapeutic potential of cannabinoids, has garnered significant attention in recent years. This literature review aims to delve into the intersection between therapeutic perspectives and the regulatory context surrounding medical cannabis. Key terms such as medical cannabis, cannabinoids, regulation, chronic pain, and multiple sclerosis (MS) will be explored to provide a comprehensive understanding of the subject.
Therapeutic applications of medical cannabis will be examined, with particular focus on its potential in managing chronic pain and alleviating symptoms associated with multiple sclerosis. Furthermore, the complex regulatory landscape surrounding medical cannabis will be analyzed, taking into account various legal frameworks, guidelines, and constraints imposed by governing bodies.This article highlights emerging scientific evidence supporting the use of medical cannabis, including the efficacy of cannabinoids in pain management and their impact on multiple sclerosis symptoms. Additionally, it will address the challenges faced by healthcare professionals, patients, and policymakers due to varying regulations across jurisdictions.
Keywords:
Medical cannabis; Cannabinoids; Regulation; Chronic pain; Multiple sclerosis
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
